Novo Nordisk’s “Super Ozempic” Trial Disappoints Again Stx– March 10, 2025FacebookTwitterPinterestGoogle+The drugmaker’s shares dropped after releasing weaker-than-expected trial results for next generation drug CagriSema, which failed to outperform Eli Lilly’s Mounjaro. Post under : #The Business of FashionFacebookTwitterPinterestGoogle+
No comments:
Post a Comment